Remdesivir COVID-19 studies. Studies show significantly increased risk of acute kidney injury

Paxlovid COVID-19 studies. Pfizer has denied access to Paxlovid for independent RCTs [Ledford]. The only non-Pfizer RCT shows no significant difference in outcomes [Liu]. [Hoertel] find that >50% of patients that died had a contraindication for Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy. Population studies often do not account for the different expected outcomes for the class of patients that seek out and receive early treatment. Recent:ANTICOV Durstenfeld Wan Kuroda Aggarwal Liu Evans. Paxlovid has been officially adopted for early treatment in 7 countries. Submit updates/corrections.